Literature DB >> 12857705

Could assessment of glioma methylene lipid resonance by in vivo (1)H-MRS be of clinical value?

P S Murphy1, I J Rowland, L Viviers, M Brada, M O Leach, A S K Dzik-Jurasz.   

Abstract

The potential clinical role of in vivo (1)H-MRS ((1)H-magnetic resonance spectroscopy) lipid methylene resonance measurements of human glioma has been assessed. 20 patients, 14 with low grade and 6 with high grade gliomas have been investigated using single voxel (1)H-MRS. Three of the low grade group had undergone transformation by clinical and imaging criteria. Short echo time (TE=20 ms, TR=2500 ms) single voxel Stimulated Echo Acquisition (STEAM) spectra with (acquisitions=64) and without (acquisitions=4) water suppression were acquired. Additionally, T(1) weighted (T(1)W) water spectra (TE=20 ms, TR=888 ms) were acquired pre- and post-injection of Gd-DTPA (0.2 mmol x kg(-1)). The T(1)W water spectra were used to determine the water proton enhancement occurring within the spectroscopic voxel. The enhancement expressed as a percentage was compared with the lipid methylene peak. All the high grade tumours had significantly higher levels of lipid than low grade tumours (p=0.002). Low grade tumours had significantly less water proton enhancement than transformers (p=0.04) and high grade tumours (p=0.001). The lipid methylene signal correlated strongly with the voxel water enhancement (r(2)=0.74, p<0.0001). The data support the view that the spectroscopically detected lipid methylene signal may be a useful criterion in grading glioma. The correlation of the lipid methylene signal with blood-brain barrier breakdown suggests that detection of a previously absent (1)H-MRS lipid methylene signal in low grade tumours might be an early indicator of transformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857705     DOI: 10.1259/bjr/16316438

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  14 in total

1.  In vivo characterization of several rodent glioma models by 1H MRS.

Authors:  Sabrina Doblas; Ting He; Debra Saunders; Jessica Hoyle; Nataliya Smith; Quentin Pye; Megan Lerner; Randy L Jensen; Rheal A Towner
Journal:  NMR Biomed       Date:  2011-09-23       Impact factor: 4.044

Review 2.  Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.

Authors:  Alexander Lin; Brian D Ross; Kent Harris; Willis Wong
Journal:  NeuroRx       Date:  2005-04

3.  Neuroradiological assessment of newly diagnosed glioblastoma.

Authors:  Srini Mukundan; Chad Holder; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

4.  Proton MR spectroscopy of cerebral gliomas at 3 T: spatial heterogeneity, and tumour grade and extent.

Authors:  Alfonso Di Costanzo; Tommaso Scarabino; Francesca Trojsi; Teresa Popolizio; Domenico Catapano; Giuseppe M Giannatempo; Simona Bonavita; Maurizio Portaluri; Michela Tosetti; Vincenzo A d'Angelo; Ugo Salvolini; Gioacchino Tedeschi
Journal:  Eur Radiol       Date:  2008-04-04       Impact factor: 5.315

5.  Chemical shift-based water/fat separation: a comparison of signal models.

Authors:  Diego Hernando; Zhi-Pei Liang; Peter Kellman
Journal:  Magn Reson Med       Date:  2010-09       Impact factor: 4.668

Review 6.  Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience.

Authors:  Andre D Furtado; Rafael Ceschin; Stefan Blüml; Gary Mason; Regina I Jakacki; Hideho Okada; Ian F Pollack; Ashok Panigrahy
Journal:  Neuroimaging Clin N Am       Date:  2017-02       Impact factor: 2.264

7.  Role of advanced MR imaging modalities in diagnosing cerebral gliomas.

Authors:  T Scarabino; T Popolizio; F Trojsi; G Giannatempo; S Pollice; N Maggialetti; A Carriero; A Di Costanzo; G Tedeschi; U Salvolini
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

8.  Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma.

Authors:  Tejas Sankar; Zografos Caramanos; Rachid Assina; Jean-Guy Villemure; Richard Leblanc; Adrian Langleben; Douglas L Arnold; Mark C Preul
Journal:  J Neurooncol       Date:  2008-07-04       Impact factor: 4.130

Review 9.  Clinical proton MR spectroscopy in central nervous system disorders.

Authors:  Gülin Oz; Jeffry R Alger; Peter B Barker; Robert Bartha; Alberto Bizzi; Chris Boesch; Patrick J Bolan; Kevin M Brindle; Cristina Cudalbu; Alp Dinçer; Ulrike Dydak; Uzay E Emir; Jens Frahm; Ramón Gilberto González; Stephan Gruber; Rolf Gruetter; Rakesh K Gupta; Arend Heerschap; Anke Henning; Hoby P Hetherington; Franklyn A Howe; Petra S Hüppi; Ralph E Hurd; Kantarci Kantarci; Dennis W J Klomp; Roland Kreis; Marijn J Kruiskamp; Martin O Leach; Alexander P Lin; Peter R Luijten; Malgorzata Marjańska; Andrew A Maudsley; Dieter J Meyerhoff; Carolyn E Mountford; Sarah J Nelson; M Necmettin Pamir; Jullie W Pan; Andrew C Peet; Harish Poptani; Stefan Posse; Petra J W Pouwels; Eva-Maria Ratai; Brian D Ross; Tom W Scheenen; Christian Schuster; Ian C P Smith; Brian J Soher; Ivan Tkáč; Daniel B Vigneron; Risto A Kauppinen
Journal:  Radiology       Date:  2014-03       Impact factor: 11.105

10.  ¹H nuclear magnetic resonance spectroscopy characterisation of metabolic phenotypes in the medulloblastoma of the SMO transgenic mice.

Authors:  S K Hekmatyar; M Wilson; N Jerome; R M Salek; J L Griffin; A Peet; R A Kauppinen
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.